Arcutis Biotherapeutics, Inc. (ARQT) — Stock Valuation & Research

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical…

ARQT key statistics

Price$32.29
Market cap$4.06B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range19.295-33.3
Beta1.63

Explore ARQT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.